Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas

Journal of Neuro-Oncology

Volumn 89, Issue 1, 2008, Pages 73-87

  Panagopoulos, Alexandros Theodoros ^a   Lancellotti, Carmen Lucia Penteado ^a   Veiga, José Carlos Esteves ^a   de Aguiar, Paulo Henrique Pires ^b   Colquhoun, Alison ^b  

^a Santa Casa Hospital   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Angiogenesis; Cyclooxygenase; Fatty acid; Meningioma; Oedema

Indexed keywords

CD45 ANTIGEN; CYCLINE; CYCLOOXYGENASE 2; FATTY ACID; FATTY ACID BINDING PROTEIN; GELATINASE A; GELATINASE B; HERMES ANTIGEN; HYALURONIC ACID; ICOSANOID; KI 67 ANTIGEN; PARAFFIN; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER INVASION; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; EDEMA; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; FEMALE; HUMAN; HUMAN TISSUE; ICOSANOID METABOLISM; MALE; MENINGIOMA; MICROVASCULATURE; MITOSIS INDEX; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TISSUE SECTION; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; CELL ADHESION MOLECULES; CELL PROLIFERATION; CHILD; CYCLOOXYGENASE 2; EICOSANOIDS; FATTY ACIDS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICROCIRCULATION; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 46949097393     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9588-3     Document Type: Article

References (67)

1. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD (1993) Epidemiology of intracranial meningioma. Cancer 72(3):639-648
2. Louis DN, Scheithauer BW, Budka H, Von Deimling A, Kepes JJ (2000) Meningiomas. In: Kleihues P, Cavenee WK (eds) Pathology and genetics of the tumors of the nervous system: World Health Organization classification of tumours. IARC Press, Lyon, pp 176-184
3. Riemenschneider MJ, Perry A, Reifenberger G (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5:1045-1054
4. Heinrich B, Hartmann C, Stemmer-Rachamimov AO, Louis DN, MacCollin M (2003) Multiple meningiomas: Investigating the molecular basis of sporadic and familial forms. Int J Cancer 103(4):483-488
5. Lusis E, Gutmann DH (2004) Meningioma: An update. Curr Opin Neurol 17(6):687-692
6. Perry A, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH (2000) Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59(10):872-879
7. Ragel BT, Jensen RL (2005) Molecular genetics of meningiomas. Neurosurg Focus 19(5):E9
8. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-Demasters BK, Perry A (2001) Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications. J Neuropathol Exp Neurol 60(6):628-636
9. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF (2000) The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 9(11):1567-1574
10. Murakami M, Hashimoto N, Takahashi Y, Hosokawa Y, Inazawa J, Mineura K (2003) A consistent region of deletion on 1p36 in meningiomas: identification and relation to malignant progression. Cancer Genet Cytogenet 140(2):99-106
11. Korshunov A, Cherekaev V, Bekyashev A, Sycheva R (2007) Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J Neurooncol 81:131-137
12. Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D (2002) Radiation-induced meningioma: A descriptive study of 253 cases. J Neurosurg 97(5):1078-1082
13. Dweik A, Maheut-Lourmiere J, Lioret E, Jan M (1995) Radiation-induced meningioma. Childs Nerv Syst 11(11):661-663
14. Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, Patsouris E (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43(3):280-290
15. Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: Prognostic considerations. J Neurosurg 86(1):113-120
16. Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neurooncol 70(2):183-202
17. Verhagen A, Go KG, Visser GM, Blankenstein MA, Vaalburg W (1995) The presence of progesterone receptors in arachnoid granulations and in the lining of arachnoid cysts: Its relevance to expression of progesterone receptors in meningiomas. Br J Neurosurg 9(1):47-50
18. Zhao X, Teng LZ, Wang ZG, Xin T, Wei SC (2007) Expression and significance of glucocorticoid receptor alpha in meningiomas. J Clin Neurosci 14(4):359-363
19. Whittle IR, Smith C, Navoo P, Collie D (2004) Meningiomas. Lancet 363(9420):1535-1543
20. Domingo Z, Rowe G, Blamire AM, Cadoux-Hudson TA (1998) Role of ischaemia in the genesis of oedema surrounding meningiomas assessed using magnetic resonance imaging and spectroscopy. Br J Neurosurg 12(5):414-418
21. Pistolesi S, Fontanini G, Camacci T, De Ieso K, Boldrini L, Lupi G, Padolecchia R, Pingitore R, Parenti G (2002) Meningioma-associated brain oedema: The role of angiogenic factors and pial blood supply. J Neurooncol 60(2):159-164
22. Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K (1999) Peritumoral brain edema associated with meningioma: Influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 85(4):936-944
23. Lieu AS, Howng SL (2000) Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 38(1):45-52
24. Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatr 20(1):22-39
25. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL (1985) Meningioma: Analysis of recurrence and progression following neurosurgical resection. J Neurosurg 62(1):18-24
26. Kallio M, Sankila R, Hakulinen T, Jaaskelainen J (1992) Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. Neurosurgery 31(1):2-12
27. Palma L, Celli P, Franco C, Cervoni L, Cantore G (1997) Long-term prognosis for atypical and malignant meningiomas: A study of 71 surgical cases. J Neurosurg 86(5):793-800
28. Dietemann JL, Heldt N, Burguet JL, Medjek L, Maitrot D, Wackenheim A (1982) CT findings in malignant meningiomas. Neuroradiology 23(4):207-209
29. Ide M, Jimbo M, Kubo O, Yamamoto M, Imanaga H (1992) Peritumoral brain edema associated with meningioma histological study of the tumor margin and surrounding brain. Neurol Med Chir 32(2):65-71
30. Mattei TA, Mattei JA, Ramina R, Aguiar PH, Plese JP, Marino R Jr (2005) Edema and malignancy in meningiomas. Clinics 60(3):201-206
31. Pistolesi S, Boldrini L, Gisfredi S, de Ieso K, Camacci T, Caniglia M, Lupi G, Leocata P, Basolo F, Pingitore R, Parenti G, Fontanni G (2004) Angiogenesis in intracranial meningiomas: Immunohistochemical and molecular study. Neuropathol Appl Neurobiol 30:118-125
32. Deininger MH, Weller M, Streffer J, Mittelbronn M, Meyermann R (1999) Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol 98:240-244
33. Nathoo N, Barnett GH, Golubic M (2004) The eicosanoid cascade: Possible role in gliomas and meningiomas. J Clin Pathol 57(1):6-13
34. Lin CCD, Kenyon L, Hyslop T, Hammond E, Andrews DW, Curran WJ, Dicker AP (2003) Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. Am J Clin Oncol 26(4 Suppl 2):S98-S102
35. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 103(3):508-517
36. Chmurzynska A (2006) The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism. J Appl Genet 47(1):39-48
37. Liang Y, Bollen AW, Aldape KD, Gupta N (2006) Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 6:97
38. Denizot Y, de Armas R, Caire F, Pommepuy I, Truffinet V, Labrousse F (2006) Platelet-activating factor and human meningiomas. Neuropathol Appl Neurobiol 32:674-678
39. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2007) Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109:588-597
40. McKeever PE (1998) Insights into brain tumors gained through immunohistochemistry and in situ hybridization of nuclear and phenotypic markers. J Histochem Cytochem 46(5):585-594
41. Roser F, Samii M, Ostertag H, Bellinzona M (2004) The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien) 146:37-44
42. Quiñones-Hinojosa A, Sanai N, Smith JS, McDermott MW (2005) Techniques to assess the proliferative potential of brain tumors. J Neurooncol 74:19-30
43. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W (2006) Histopathologic indicators of recurrence in meningiomas: Correlation with clinical and genetic parameters. Virchows Arch 449:529-538
44. Otsuka S, Tamiya T, Ono Y, Michiue H, Kurozumi K, Daido S, Kambara H, Date I, Ohmoto T (2004) The relationship between peritumoural brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. J Neurooncol 70:349-357
45. Paek SH, Kim CY, Kim YY, Park IA, Kim MS, Kim DG, Jung HW (2002) Correlation of clinical and biological parameters with peritumoral edema in meningioma. J Neurooncol 60:235-245
46. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y (2006) Prognostic value of expression of vascular endothelial growth factor and its Flt-1 and Kdr receptors in stage I non-small-cell lung cancer. Lung Cancer 53:91-96
47. Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469-478
48. Kiliç T, Bayri Y, Ozduman K, Acar M, Diren S, Kurtkaya O, Ekinci G, Bugra K, Sav A, Ozek MM, Pamir MN (2002) Tenascin in meningioma: expression is correlated with anaplasis, vascular endothelial growth factor expression and peritumoral edema but not with tumor border shape. Neurosurgery 51:183-193
49. Tchilian EZ, Beverly PCL (2006) Altered CD45 expression and disease. Trends Immunol 27(3):146-153
50. Okada M, Miyake K, Matsumoto Y, Kawai N, Kunishio K, Nagao S (2004) Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas. J Neurooncol 66:29-37
51. Von Randow AJU, Schindler S, Tews DS (2006) Expression of extracellular matrix degrading proteins in classic, atypical and anaplastic meningiomas. Pathol Res Pract 202:365-372
52. Okuducu AF, Zils U, Michaelis SAM, Michaelides S, von Deimling A (2006) Ets-1 is up-regulated together with its target gene products matrix metalloproteinase-2 and matrix metalloproteinase-9 in atypical and anaplastic meningiomas. Histopathology 48:836-845
53. Kiran MS, Kumar VBS, Viji RI, Sudhakaran PR (2006) Temporal relationship between MMP production and angiogenic process in HUVECS. Cell Biol Int 30:704-713
54. Rosell A, Ortega-Aznar A, Alvarez-sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J (2006) Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37:1399-1406
55. Tejima E, Zhao BQ, Tsuji K, Rosell A, van Leyen K, Gonzalez RG, Montaner J, Wang X, Lo EH (2007) Astrocytic induction of matrix metalloproteinase-9 and edema in brain hemorrhage. J Cereb Blood Flow Metab 27(3):460-468
56. Schwechheeimer K, Zhou L, Birchmeier W (1998) E-cadherin in human brain tumours: Loss of immunoreactivity in malignant meningiomas. Virchows Arch 432:163-167
57. Shimada S, Ishizawa K, Hirose T (2005) Expression of E-cadherin and catenins in meningioma: Ubiquitous expression and its irrelevance to malignancy. Pathol Int 55:1-7
58. Lusis EA, Chicoine MR, Perry A (2005) High throughput screening of meningioma biomarkers using tissue microarray. J Neurooncol 73:219-223
59. Brunner EC, Romeike BFM, Jung M, Comtesse N, Meese E (2006) Altered expression of beta-catenin/E-cadherin in meningiomas. Histopathology 49:178-187
60. Turley EA, Noble PW, Bourguignon LYW (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277(7):4589-4592
61. Yang CW, Su JY, Tsou AP, Chau GY, Liu HL, Chen CH, Chien CY, Chou CK (2005) Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example. Biochem Biophys Res Commun 330:489-497
62. Slevin M, Krupinski J, Gaffney J, Matou S, West D, Delisser H, Savani RC, Kumar S (2007) Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 26(1):58-68
63. Suzuki SO, Iwaki T, Kitamoto T, Mizoguchi M, Fukui M, Tateishi J (1996) Differential expression of CD44 variants among meningioma subtypes. J Clin Pathol Mol Pathol 49:M140-M146
64. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG (2004) Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 36:1046-1069
65. Zhang Y, Thant AA, Machida K, Ichigotani Y, Naito Y, Hiraiwa Y, Senga T, Sohara Y, Matsuda S, Hamaguchi M (2002) Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res 62:3962-3965
66. Gotte M, Yip GW (2006) Heparanase, hyaluronan and CD44 in cancers: A breast carcinoma perspective. Cancer Res 66(21):10233-10237
67. Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, McCarthy JB, Bissell MJ, Turley EA (2006) Rhamm-/- fibroblasts are defective in CD44-mediated ERK1, 2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 175(6):1017-1028